Setting Drug Product Specifications: Release Limits, Shelf-Life Limits, Justification

A specification is not a list of tests copied from a pharmacopoeia; in the dossier it is a set of tests, methods and limits that you must justify with data from your own batches.

What section 3.2.P.5 expects

The control of the drug product covers the specification, the analytical procedures, their validation, batch analyses, the characterisation of impurities and the justification of the specification. ICH Q6A sets out the principles for chemical substances, including the idea of universal tests, such as description, identification, assay and impurities, and specific tests that apply to particular dosage forms.

The justification should explain why each test and limit was chosen. Limits are expected to reflect clinical relevance, manufacturing capability, stability behaviour and pharmacopoeial requirements, not simply the range observed on a handful of batches.

Release versus shelf-life

Where a product degrades, the limit at release may be tighter than the limit at the end of shelf life. This is acceptable when it is justified by stability data, and the dossier should state clearly which limits apply when. Applicants who propose the same wide limit at both stages without a rationale invite questions.

Related impurity limits should be set with reference to the ICH Q3B approach for degradation products in drug products, with qualification where limits exceed the thresholds. Residual solvents and elemental impurities are addressed through ICH Q3C and Q3D, and mutagenic impurities through ICH M7.

Common weaknesses

  • Limits derived only from a small number of development or exhibit batches.
  • No rationale for dissolution or particle-size acceptance criteria.
  • Tests present in the dossier but absent from the routine control strategy, or the reverse.
  • Specification and shelf-life limits that disagree between Module 3 and the stability protocol.
  • Impurity limits that exceed identification or qualification thresholds without justification.

Keeping specifications alive

A specification should be reviewed as commercial data accumulate. Trending of results can show that limits are too wide to protect quality or too tight to be met reliably. Tightening or widening a limit generally requires a variation, so it is cheaper to set realistic limits at the outset.

For generic products, the pharmacopoeial monograph is the starting point, but if the product has a different impurity profile or manufacturing route, additional controls may be needed.

Questions to ask before filing

Can you explain, in one sentence per test, why the limit is what it is? Are the batches behind the limits representative of commercial scale? Do the limits in Module 3, the stability protocol and the batch release procedure match exactly? If any answer is uncertain, strengthen the justification before the assessor asks. Remember too that pharmacopoeial requirements apply regardless of what the dossier proposes, so check the current monograph at the time of filing.

How PQRA helps

PQRA reviews draft specifications and their justifications before submission, checks consistency between Module 3, the stability data and the Module 2 summary, and helps prepare responses when assessors challenge limits.

Talk to us about your dossier: Contact PQRA

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *